The Cambridge, Massachusetts-based company’s stock recently traded at $8.99 a share, down 15.4% on higher-than-average volume.
Patricia Keller, senior scientist at Constellation, made the poster presentation titled "targeting epigentic dysregulation in bladder cancer through inhibition of EZH2" at the Bladder Cancer: Transforming the Field meeting of the American Association for Cancer Research in Denver.
The poster discusses results of Constellation’s work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models, exploring whether ARIDA mutation status affected responsiveness to CPI-0209 treatment, according to a statement.
ARID1A, a protein that is a key component of the SWI/SNF chromatin remodeling complex, is mutated in about 25% of muscle-invasive bladder cancers, the company said.
Constellation used CPI-0209 in long-term phenotypic growth assays in a panel of 21 bladder cancer cell lines, demonstrating preferential treatment sensitivity that correlated with increased cell death in cell lines harboring ARID1A mutations. Transcriptional profiling after CPI-0209 treatment showed widespread activation of EZH2 target gene expression, the company said.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham